Table 3.

Effects of Lipid Apheresis in Familial Hypercholesterolemia.

Study	Country	Number of Patients	Years of Follow Up	Proportion Free of Cardiovascular Events	LDL-C Reduction
Mabuchi et al. 1998 [72]	Japan	130 heterozygotes: •43 with drug therapy + apheresis •87 with intensive medical therapy alone	6	•90% with drug therapy + apheresis •64% with intensive medical therapy •p-value = 0.0088	•58% with drug therapy + apheresis •28% with intensive medical therapy •p-value <0.0001
Masaki et al. 2005 [89]	Japan	18 heterozygotes: •17 with statin therapy + apheresis	10	•94.4% at 6 years •88.9% at 10 years	Not Applicable
Khoo et al. 2016 [90]	Malaysia	10 homozygotes and 5 heterozygotes: •15 maximal medical therapy + apheresis	10	•100%	•55.6% in homozygous group •57.8% in heterozygous group

Abbreviations: LDL-C = low-density lipoprotein-cholesterol.